Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.
Thiazolidinediones (TZDs) or glitazones are agents that are widely used for the treatment of type 2 diabetes mellitus. These drugs have a multitude of therapeutic effects including reduction in insulin resistance and hyperglycaemia, anti-inflammatory effects and amelioration of hypertension, microalbuminuria and hepatic steatosis. The TZD molecular target, peroxisome proliferator-activated receptor gamma (PPARgamma), a nuclear transcription factor, is expressed diffusely in humans, including many tissues comprising the cardiovascular and renal systems. This suggests a potential for TZDs to elicit perturbing effects on these systems, which are independent of their effects on glucose and lipid metabolism. One of the most common adverse effects of TZDs is fluid retention, which can result in, or exacerbate, oedema and congestive heart failure (CHF). The frequency of peripheral oedema is approximately 5% when TZDs are used in mono- or combination oral therapy, and about 15% when used with insulin. Patients with type 2 diabetes are at high risk of myriad morbid complications, including CHF. The development of CHF, particularly in the elderly, is a harbinger of premature mortality. TZD-induced oedema is largely peripheral, may have its origins in changes in haemodynamics, with some contribution from molecules, which regulate cell and tissue permeability (e.g. vascular endothelial growth factor and protein kinase Cbeta), and remains the preponderant manifestation of TZD-induced fluid retention even in those with existing heart failure. Preclinical and pilot clinical data attest to the fact that at least part of the fluid retention derives from a direct effect of TZDs on sodium reabsorption via the renal medullary collecting duct, a mechanism that is sensitive to diuretic agents that have this nephron segment as their site of action, in whole or in part (spironolactone, amiloride and hydrochlorothiazide). Our review suggests various potential clinical strategies by which TZD-induced fluid retention might be effectively monitored and addressed.
Karalliedde
Janaka
J
Cardiovascular Division, King's College London School of Medicine, Guy's Hospital, King's College London, London, UK. j.karalliedde@kcl.uk
Buckingham
Robin E
RE
D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy; D019468:Disease Management; D004232:Diuretics / Q000627:therapeutic use; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology; D006333:Heart Failure / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D009765:Obesity / Q000150:complications / Q000188:drug therapy; D047495:PPAR gamma / Q000819:agonists; D045162:Thiazolidinediones / Q000009:adverse effects*
D004232:Diuretics; D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones